ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Half of clinical TKI resistance is free of BCR::ABL1 kinase domain mutations,10 suggesting BCR::ABL1 kinase‐independent resistance mechanisms, the primary form of TKI resistance in CML LSCs.11